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Abstract
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Background—Atrazine suppression of the LH surge slowly develops over time and peaks after 4
days; sensitivity to atrazine decreases after 8 or 14 days of dosing. Adaptation of the LH response
was correlated with increased phase I and phase II liver enzyme activity/expression.
Methods—The effect of atrazine on the LH surge was evaluated in female Sprague-Dawley rats
administered 100 mg/kg/day atrazine by gavage for 1, 2, 3, or 4 consecutive days or 6.5, 50, or 100
mg/kg/day atrazine for 4, 8, or 14 days.
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Results—No statistically significant effects of atrazine were seen on peak plasma LH or LH area
under the curve (AUC) after one, two, or three doses of 100 mg/kg/day. Four daily doses of 50 or
100 mg/kg atrazine significantly reduced peak LH and LH AUCs, whereas 6.5 mg/kg/day had no
effect. After 8 or 14 days of treatment, statistically significantly reduced peak LH and LH AUC
were observed in the 100 mg/kg/day dose group, but not in the 6.5 or 50 mg/kg/day dose groups,
although significantly reduced LH was observed in one sample 9 hr after lights-on in the 50
mg/kg/day dose group on day 14. The number of days of treatment required to achieve a
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significant suppression of the LH surge is consistent with the repeat-dose pharmacokinetics of the
chlorotriazines.
Conclusion—The apparent adaptation to the effect of atrazine on the LH surge after 8 or 14 days
may be related to the induction of phase I or, more likely, phase II metabolism observed in this
study after 8 days, or to a decreased sensitivity of the hypothalamic-pituitary-adrenal axis or an
homeostatic adaption of the effect of atrazine on the LH surge mechanism.
Keywords
LH surge; gavage; atrazine; sensitivity; adaptation; phase I metabolism; phase II metabolism

Introduction
Author Manuscript

The chlorotriazine herbicide, atrazine (2-chloro-4-[ethylamino]-6-[isopropylamino]-striazine; ATZ), is widely used in agriculture to control broadleaf and grassy weeds (Bridges,
2008). ATZ exerts its herbicidal effects by inhibiting the electron transport system necessary
for photosynthesis (Good, 1961; Tischer and Strotmann, 1977). When administered by
gavage to ovariectomized female Sprague-Dawley (SD) rats, ATZ suppresses the estrogeninduced or the estrogen + progesterone-induced luteinizing hormone (LH) surge (Cooper et
al., 2000; McMullin et al., 2004; Foradori et al., 2009a). ATZ also reduces the endogenous
LH surge that occurs on the afternoon of proestrus in intact rodents (Foradori et al., 2014).
The mechanism of this action is unclear, but it appears that ATZ’s suppression of the
gonadotropin-releasing hormone and LH surge is mediated centrally, and not at the level of
the anterior pituitary (Cooper et al., 2007).

Author Manuscript

The effect of ATZ on the LH surge occurs after three or four daily gavage doses of greater
than 50 mg/kg/day (Goldman et al., 2013). These effects of ATZ are short-lived and
disappear within 4 days of the termination of dosing (Foradori et al., 2009a). The
progressive increase in the magnitude of the effect of ATZ on the LH surge observed over 4
days of dosing may in part be explained by the rapid pharmacokinetics of atrazine and its
chlorotriazine metabolites (Campbell et al., 2016). Thus, the amount of time needed to
achieve 90% of the steady-state plasma concentration of diaminochlorotriazine (DACT)
following an ATZ gavage dose of 50 mg/kg/day was 11 hr, and the half-life for clearance of
DACT from plasma was 11.5 hr. ATZ and its two mono-dealkylated metabolites
(deethylatrazine [DEA] and deisopropylatrazine [DIA]) were cleared within 2 to 4 hr of
dosing, and hence never achieved sustained blood levels with once-a-day dosing (Campbell
et al., 2016).

Author Manuscript

To determine if the effect of ATZ on the estradiol-induced LH surge adapts over time, the
LH surge was evaluated in young-adult female SD rats administered ATZ by oral gavage at
doses of 6.5, 50, and/or 100 mg/kg/day for 1, 2, 3, 4, 8, or 14 days. Since liver enzymes
responsible for the oxidative (phase I) and conjugative (phase II) metabolism of ATZ are
inducible (Islam et al., 2002), liver samples were collected and analyzed for the expression
of hepatic enzymes known to be involved in ATZ metabolism. We found that four daily
doses of 50 or 100 mg/kg ATZ significantly reduced peak LH and LH area under the curve
(AUC), whereas 8 or 14 days of dosing reduced peak LH and LH AUC in the 100 mg/kg/day
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dose group, but not in the 6.5 or 50 mg/kg/day dose groups. In the 100 mg/kg/day dose
group, group mean body weight (BW) loss was positively correlated with the ATZ dose, but
inversely correlated with LH AUC. Individual animal weight loss was not predictive of LH
AUC after 4, 8, or 14 days of ATZ treatment. Although several CYP450 enzymes were
induced after 8 or 14 days of treatment (most noticeably, CYP2B2B mRNA expression),
overall CYP450 enzyme expression was poorly predictive of the effects of ATZ on LH AUC.
In contrast, the expression of mRNA for glutathione-s-transferase (GST) isoforms was
strongly induced by 8 days of ATZ treatment at 50 mg/kg/day, but not after 4 or 14 days of
dosing. The overall expression of glutathione (GSH) and the GST isoenzymes were doseand time-dependently induced by ATZ, and were predictive of reduced LH AUC after 4, 8,
or 14 days of treatment.

Materials and Methods
Author Manuscript

ANIMALS
Eight- to 9-week-old female SD rats (Crl:CD(SD)) were received in two batches from
Charles River Laboratories, Inc. (Raleigh, NC) and maintained in AAALAC-approved
animal facilities at WIL Research Laboratories, LLC (Ashland, OH). Animals were housed
individually in clean, suspended, wire-mesh cages. The animals were maintained in an
environmentally controlled room (22 ± 3°C; 50 ± 20% humidity) on a 14-hr light/10-hr dark
photoperiod (lights on at 05:00 hr, off at 19:00 hr) with water and food (Rodent LabDiet,
PMI Nutrition International, LLC) available ad libitum. During the first 2 weeks of the 3- to
4-week acclimation period, all animals in experiments 1 and 2 were monitored for estrous
cyclicity by taking daily vaginal swabs. Only those animals showing regular 4-day estrous
cycles were retained for use in these studies.

Author Manuscript

Seven days before randomization, regularly cycling females were acclimated to the dosing
procedure by administering a daily oral gavage dose of the vehicle (1% methylcellulose in
deionized water) at a dose volume of 5 ml/kg. At the end of the acclimation period, 25
animals were randomly assigned to either the vehicle control group or the ATZ-treated group
(experiment 1), or to either the vehicle control group or one of three ATZ-treated groups
(experiment 2).
ATRAZINE FORMULATION AND ADMINISTRATION

Author Manuscript

ATZ was supplied by Syngenta Crop Protection, LLC, as an analytically certified, 98.8%
pure, white powder that was stable for use during the period of the study. ATZ was prepared
approximately weekly as a suspension in 1% methylcellulose and deionized water at
concentrations of 1.3, 5, or 20 mg/ml. Suspensions were stored refrigerated (at 2 to 8°C)
until use. Sample storage stability and sample homogeneity were established by highpressure liquid chromatography before study conduct. The concentration of ATZ, which was
assessed in every dose suspension by high-pressure liquid chromatography, ranged from
94.7 to 101% of target.
In experiment 1, 10 to 15 animals were randomly assigned to either the control (N = 10) or
an ATZ-treated group (N = 15) in each of four cohorts. The cohorts of animals were
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administered either the vehicle (5 ml/kg 1% aqueous methylcellulose suspension) or ATZ
(100 mg/kg/ day) by gavage for either 1, 2, 3, or 4 days. Dosing occurred immediately after
lights on at approximately 05:00 hr. In experiment 2, animals were randomly assigned to
four separate cohorts of 25 animals each and dosed daily by oral gavage with either the
vehicle (0 mg/ kg/day) or one of three doses of ATZ (6.5, 50, or 100 mg/ kg/day) for either 4
days, 8 days, or 14 consecutive days before blood sampling.
SURGICAL PROCEDURES BEFORE BLOOD COLLECTION

Author Manuscript

Three days before the scheduled day of blood collection, each animal was anesthetized with
isoflurane, and a polyurethane catheter was implanted into the femoral vein. The opposite
end of the cannula was tunneled subcutaneously to exit the skin in the scapular region. The
catheter was attached to an SAI Quick Connect™ with an injection cap and a jacket adaptor.
A bilateral ovariectomy was performed, and a 12- to 14-mm-long Silastic capsule (0.062″
internal diameter × 0.125″ outside diameter) containing estradiol benzoate (4 mg/ml in
sesame oil) was implanted subcutaneously in the right flank region. This procedure was
performed in the morning (06:00 hr–12:00 hr). Implantation of the estradiol capsule
produces a synchronized cohort of animals with estradiol blood levels comparable to intact
animals in proestrus, resulting in a daily afternoon surge in LH levels (Legan and Karsch,
1975).
BLOOD COLLECTION

Author Manuscript

Four days following ovariectomy and estradiol capsule implantation, blood samples were
collected from each animal at 6, 9, 11, 13, 15, and 18 hr after lights on (11:00, 14:00, 16:00,
18:00, 20:00, and 23:00 hr, respectively), to capture the profile of the LH surge, which in our
colony peaks at 11–13 hr after lights on (16:00–18:00 hr). For each rat, blood samples were
collected within 10 min of the target collection time by means of the surgically implanted
femoral vein catheter. For collection times after lights out (1900 hr), samples were collected
under red-light conditions. To minimize stress to the animals during blood collection, noise
in the animal room and handling of the animals before blood collection was kept to a
minimum.
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Blood samples (0.5 ml/animal/time point) were collected into prechilled, uniquely labeled
tubes with sodium heparin as the anticoagulant. Blood samples were centrifuged, plasma
was aliquoted to two uniquely labeled polypropylene tubes, and then the samples were
stored at −70°C. All plasma samples were shipped on dry ice from WIL Research
Laboratories to the University of Arizona, College of Medicine, Phoenix, AZ. Upon receipt,
the samples were catalogued and stored at −80°C until analysis of LH concentrations by
radioimmunoassay.
LIVER SAMPLES COLLECTED AT STUDY TERMINATION
In experiment 1, liver samples collected from 5 rats/group killed on day 1, 2, 3, or 4 were
analyzed using real-time polymerase chain reaction analyses for GST mRNA expression.
Total GSH levels were evaluated using the Cayman Chemical GSH assay kit (Ann Arbor,
MI) as described by Zimmerman et al. (2017). In experiment 2, GST, GSH, and P450
analyses were conducted on liver samples collected from 5 rats/sex/group on day 4, 8, or 14.
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Each rat was anesthetized, and the abdominal cavity was opened to expose the liver. An
approximately 5 mm3 sample of liver was collected from the left and median lobes, and then
placed in individual sterile plastic tubes containing 2–5 ml of RNAlater® reagent. The
samples were refrigerated overnight at 4°C and then transferred to a freezer at −70°C, until
shipment on dry ice to Auburn University for analyses of messenger RNA (real-time
polymerase chain reaction), enzyme expression, and total protein levels (Western blots) for
the following thirteen GST liver enzymes: GSTA3, GSTA4, GSTK1, GSTM1, GSTM2,
GSTM3, GSTO1, GSTO2, GSTP1, GSTT1, GSTT2, MGST1, and MGST2. Overall GST
activity was determined in cytosolic (GSTC) and microsomal (GSTM) fractions
(Zimmerman et al., 2017).
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After liver samples were collected from the left and median lobes, the animal was cardiacperfused with physiologically buffered saline until it was exsanguinated. The right lobe of
the liver was collected, weighed, and flash-frozen in liquid nitrogen, and were then shipped
on dry ice to Auburn University for analyses of mRNA levels for the following 29 P450 liver
enzymes: CYP17A1, CYP1A2, CYP26A1, CYP26C1, CYP27A1, CYP2B2, CYP2B3,
CYP2C22, CYP2C23, CYP2C37, CYP2C6, CYP2C7, CYP2D2, CYP2D4, CYP2E1,
CYP2F4, CYP2R1, CYP2T1, CYP3A18, CYP3A23/ 3A1, CYP3A9, CYP4A3, CYP4B1,
CYP4F1, CYP4F4, CYP4F6, CYP7A1, CYP7B1, and CYP8B1B. In addition, total GSH
levels (nmol GSH/mg protein) were measured and standardized to total protein levels in the
supernatant of homogenized, centrifuged liver samples (Zimmerman et al., 2017).
RADIOIMMUNOASSAY FOR LH

Author Manuscript

Plasma LH concentrations were measured at the University of Arizona, using reagents
provided by the National Hormone and Peptide Program (NHPP) (Harbor UCLA Medical
Center, Torrance, CA). Rat LH-RP3 was used to create a standard curve (range: 10.0 to
0.0049 ng). Tracer ovine LH (oLH, NHPP) was iodinated using the chloramine-T method by
the Colorado State University peptide assay core and then shipped to the University of
Arizona within 3 days of iodination. For assay, plasma samples were incubated overnight at
4°C with antiserum (NIDDK-Anti-rLH-SII; diluted 1:300,000). Following incubation,
iodinated oLH was added to each tube (~10,000 cpm/tube) and incubated overnight at 4°C.
Bound LH was separated from free LH by incubation with goat anti-rabbit γ globin (NHPP,
Harbor UCLA Medical Center, 1:1000) in 5% polyethylene glycol (Fisher Biotech;
BP233-1), followed by centrifugation in a Beckman J6B centrifuge (2000 × g - 15 min). The
mean intra-assay and inter-assay coefficients of variation were 11.5% and 3.0%,
respectively, and the average lower limit of quantitation was 0.61 ng/ml.

Author Manuscript

DATA ANALYSIS
LH concentrations that fell outside the upper and lower limits of the assay (15 and 85%
bound, respectively) were diluted appropriately, if sample volume allowed, and reassayed
until the sample fell within the analytical range. In the event that a sample was below the
lower limit of quantitation, the limit of quantitation value was used so as not to bias the data
against the appearance of low values. LH levels were first analyzed using a two-way analysis
of variance (ANOVA) to evaluate the effects of dose, time, and the interaction between dose
and time. Posthoc analysis was performed using the Bonferroni method (Motulsky, 1995).
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For peak LH levels and LH AUC, data were analyzed by one-way ANOVA followed by
posthoc analysis using the Dunnett’s t test (Dunnett, 1964). Statistical comparisons of group
mean LH within dose groups across treatment days were done using a one-sided t test. For
all analyses, the level of statistical significance was set at p ≤ 0.05. Numerical values are
reported as the mean ± SEM.
Microsoft Excel was used to calculate the correlation, expressed as a coefficient of
determination (R2), between individual animal peak LH and LH AUC. Since LH AUC was
correlated with changes in BW during dosing, an analysis of covariance was conducted on
peak LH and LH AUC, where the covariate was BW change during the treatment period.
Regression equations based on the relationship between individual animal weight change
during treatment and LH AUC were calculated, and the statistical significance of the
correlation (R2), was assessed using a two-sided t test.

Author Manuscript
Author Manuscript

Group mean P450 liver mRNA enzyme expression, measured in liver samples collected after
4, 8, or 14 days of ATZ treatment, were calculated, and the statistical significance of the
differences between ATZ-treated groups and the control group was evaluated using a twoway analysis of variance, followed by Bonferroni post hoc tests (Motulsky, 1995). Since the
expression of mRNA for CYP2B2 was dose-dependently induced by ATZ, individual animal
CYP2B2 expressions were correlated with LH AUC data from the same animals. For this
analysis, individual LH AUC and P450 enzyme activity values were normalized as
percentages of the control group means. The statistical significance of the R2 between LH
AUC and CYP enzyme mRNA expression was determined, and linear regression equations
were calculated after 4, 8, and 14 days of ATZ treatment. The statistical significance of
correlation between these parameters (R2) was assessed using a two-sided t test. A similar
analysis was conducted for the isoforms of GST mRNA expression after 4, 8, or 14 days of
ATZ treatment (Zimmerman et al., 2017). However, since GST mRNA expression increased
in a dose-dependent manner after 4, 8, or 14 days of ATZ treatment for all GST isoforms,
the average fold-change in GST mRNA expression was calculated for each individual
animal, relative to the control group mean, and correlated with its LH AUC by calculating
the R2.
In some graphical presentations, the relationships between group mean LH AUC and group
mean BW loss, group mean CYP2B2, and GST enzyme expression were plotted. However,
the R2 and the linear regression functions shown in these figures were based on an analysis
of individual animal data, not group means.

Author Manuscript

Linear regressions with LH AUC regressed on multiple independent variables (covariates)
were also used to analyze the relative explanatory ability of different combinations of day,
dose, BW loss, seven different CYP enzymes, and two GST enzymes. Twelve different mean
LH AUC values (three durations [4, 8, and 14 days] and four doses [0, 6.5, 50, and 100
mg/kg/day]) were regressed on different combinations of the mean values of the covariates.
Regressions with higher values of the R2 (i.e., fractions of variations explained) were
considered to be better predictors of LH AUC.
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Results
BW, FOOD CONSUMPTION, AND CLINICAL SIGNS DATA FROM EXPERIMENTS 1 AND 2

Author Manuscript

Group mean BW reductions were not statistically significant after one, two, or three doses of
ATZ doses up to 100 mg/kg/day in experiments 1 and 2. Group mean BW was statistically
significantly reduced compared to controls in groups administered ATZ at doses of 50 and
100 mg/kg/ day for 4, 8, or 14 days (Fig. 1, experiment 2; data from experiment 1 not
shown). Group mean BW of the 6.5 mg/ kg/day ATZ-treated group was not statistically
significantly reduced compared with the control group mean (Fig. 1, experiment 2). In
addition to the effect of ATZ treatment on BW, the surgical procedure carried out 3 days
prior to blood collection (after 4, 8, or 14 days of treatment) also reduced BWs in the vehicle
control and the ATZ-treated groups. The group × day interaction was not statistically
significant, indicating that the effect of surgery on BW was similar in the control and the
ATZ-treated groups.
Food consumption tended to be less in ATZ-treated groups compared to controls, but it was
highly variable, and none of the differences were statistically significant (data not shown).
There were no treatment-related clinical symptoms observed in ATZ-treated rats,
irrespective of dose level or the number of doses received.
LH SURGE

Author Manuscript

Experiment 1: Effect of 1, 2, 3, or 4 days of ATZ treatment on the LH surge—
The results of the statistical analyses of the LH data collected in experiment 1 (i.e., LH
surge, peak LH, and LH AUC) after one, two, three, or four ATZ doses of 100 mg/kg/ day
are presented in Table 1. No statistically significant effect of a single dose of ATZ (100
mg/kg/day) was observed for the estradiol-induced LH surge (Fig. 2A), as indicated by an
absence of a treatment effect in the ANOVA or by any effect on LH, peak LH, or LH AUC,
based on paired statistical comparisons using Bonferroni’s or Student’s t tests (Table 1).
Similar results were obtained after two or three daily doses (Fig. 2B and 2C), except that a
statistically significant overall treatment effect was indicated by the statistically significant
ANOVA, but not by the more conservative Bonferroni t test. Neither peak LH nor LH AUC
was statistically significant (Student’s t test) after two or three ATZ doses. In contrast, after
four daily doses of 100 mg/kg ATZ, a statistically significant reduction in the LH surge was
observed (Table 1; graphical data not shown), as indicated by a significant ANOVA, a
significant reduction in LH at 13:00 hr. (Bonferroni t test), and statistically significantly
reduced peak LH and LH AUC (Student’s t test).

Author Manuscript

Experiment 2: Effects of 4, 8, or 14 days of ATZ dosing on the LH surge—The
administration of ATZ daily by gavage at doses of 50 or 100 mg/kg to female SD rats for 4
days statistically significantly reduced the LH surge, as indicated by a statistically significant
treatment effect shown by ANOVA, with significant reductions in LH at 11:00 and 13:00 hr,
based on the Bonferroni t test, and with statistically significant reduced peak LH and LH
AUC, based on the Student’s t test. An overall treatment effect on LH was also indicated in
the 6.5 mg/kg/day dose group by a statistically significant Bonferroni t test at 1300 hr,

Birth Defects Res. Author manuscript; available in PMC 2019 February 15.

Breckenridge et al.

Page 8

Author Manuscript

although no differences between the control and the 6.5 mg/kg ATZ treated groups were
evident, based upon peak LH or LH AUC (Figs. 2D–F and 3, and Table 1).
In contrast, after 8 days of ATZ administration, the effect of treatment on the LH surge, peak
LH, or LH AUC was only observed in the 100 mg/kg/day dose group, but not in either the
6.5 or 50 mg/kg/day dose groups (Figs. 2 and 3). By 14 days, the LH surge was statistically
significantly reduced in the 50 and 100 mg/kg/day dose groups at 1400 and 1600 hr; peak
LH and LH AUC were reduced in the 100 mg/kg/day group, but not in the 50 mg/kg/day
group. There were no statistically significant effects of 14 days of ATZ treatment on any LH
parameter in the 6.5 mg/kg/day dose group.

Author Manuscript

Peak LH was highly-correlated with LH AUC (R2 = 0.94; p < 0.01; Supplementary Fig. S1).
The relationship was independent of the dose level or the number of dose days. Based on
these results, LH AUC was used as the covariate in all subsequent correlational analyses.
ADAPTATION OF THE EFFECT OF ATRAZINE ON THE LH AUC WITH REPEATED DOSING
The magnitude of the effect of ATZ on the LH surge, as measured by LH AUC, adapted with
repeated dosing (Fig. 4). The magnitude of the effect on the LH AUC in the 6.5 mg/kg/day
ATZ-treated group was statistically significantly less after 8 and 14 days of treatment than
after 4 days (Fig. 4). A similar pattern was present in the 50 mg/kg/day ATZ-treated group,
although none of the differences between days was statistically significant. In the high dose
group administered 100 mg/kg/day ATZ for 4, 8, or 14 days, LH AUC was significantly less
on day 4 compared with day 8, but not when compared with day 14.
CORRELATION BETWEEN LH AUC AND BW

Author Manuscript

An analysis of individual animal weight change over 4 (Supplementary Fig. S2a), 8
(Supplementary Fig. S2b), or 14 days of treatment (Supplementary Fig. S2c) indicated that
BW change was not correlated with LH AUC, irrespective of whether the animals were in
the control-, low-, mid-, or high-dose ATZ-treated groups. In an analysis of the three
covariates (BW loss during treatment, ATZ dose level, and the number of days of treatment),
BW loss alone did not account for significantly more variance in LH AUC than did the ATZ
dose level alone. The contribution of the day of treatment to the R2 was minimal (Fig. 5).
RELATIONSHIP BETWEEN THE EFFECT OF ATZ ON LIVER P450 ENZYME EXPRESSION
AND LH AUC

Author Manuscript

Although there was variability across assessment occasions, the high dose of ATZ
consistently resulted in a greater than twofold increased expression of CYP2C22, CYP2C23,
CYP2B3, CYP2E1, and CYP2B2 (Supplementary Table S1), whereas CYP1A2 and
CYP7B1 were often significantly less than controls. An assessment of the dose-response
indicated that many CYP enzymes were induced on day 8 in the 50 mg/kg/day dose group,
only to later fall back to near baseline levels by day 14 (Supplementary Table S1). In the 6.5
mg/kg ATZ treated groups, overall CYP enzyme induction was relatively weak on all
assessment occasions, with the exceptions of CYP3A9, CYP2D4, and CYP3A18, which
were most noticeably induced on days 4 and/or 8, as well as CYP2B2 on day 14. The
progressively stronger induction of CYP2B2 expression as a function of dose over time was
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indicated by a relationship between CYP2B expression and dose on days 4, 8, and 14 (Fig.
6a, Panel A; Fig. 6b). This relationship was the inverse of the dose-dependent decline in LH
AUC (Fig. 6b).
RELATIONSHIPS BETWEEN THE EFFECTS OF ATZ ON GSH LEVELS, GST ENZYME
ACTIVITY, AND LH AUC
Rats administered 100 mg/kg ATZ over 4 days of treatment displayed a progressive increase
in liver concentrations of GSH, cytosolic GST, and mitochondrial GST compared to
untreated controls (Supplementary Fig. S4). In the 100 mg/kg/day dose group, mean GST
mRNA activity increased progressively after 2 days of treatment, reached a maxima by day
8, and then fell back to control levels by day 14 (Fig. 7a).
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Isoforms of the GST enzymes also tended to be increased in rats administered 100 mg/kg
ATZ for 3, 4, 8, or 14 days when compared with groups of rats administered ATZ for only 1
or 2 days (Supplementary Fig. S5). In contrast to the results for GST mRNA, the majority of
the GST isoforms displayed a dose-dependent response to ATZ treatment, which was more
evident after 4 and 8 days than after 14 days of treatment (Supplementary Fig. S6). In
general, isoforms of specific GST enzymes in the 50 mg/kg/day dose group increased more
compared to other doses by day 8 and fell below control levels by day 14 (Supplementary
Fig. S6). The time- and dose-dependent induction of GST enzyme expression in experiment
2 was the inverse of the reduction in LH AUC observed in these same groups of rats (Fig.
7b).
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R2 calculated for LH AUC indicated that the proportion of the variance in LH AUC, after
taking into account dose and duration of treatment, was strongly affected by the covariates
for CYP2D4, GSTT1, GSTM1, and mean GST activity (Fig. 8).

Discussion

Author Manuscript

This study was designed to determine if the total number of doses of atrazine administered
by gavage to female SD rats would alter the magnitude of the effect of ATZ on the estrogeninduced surge of LH. The results indicate that 100 mg/kg ATZ reduced the LH surge (peak
LH, LH AUC) after 2 days of treatment, but these effects were not statistically significantly
different from control groups until day 4. In experiment 2, by day 4, LH levels were
significantly reduced on at least one sampling occasion in each of the ATZ-treated groups,
however, peak LH and LH AUC were significantly reduced in only the 50 and 100
mg/kg/day ATZ-treated groups. Following 8 or 14 days of ATZ treatment, there were no
effects on the LH surge in the 6.5 mg/kg/day dose group; peak LH and LH AUC were only
statistically significantly reduced in the 100 mg/kg/day ATZ group. This suggests that there
is an “adaptation” to the effect of ATZ after multiple daily doses of ATZ at levels near or
above a dose that has no effect on the LH surge (i.e., 6.5 mg/kg/day).
These results are consistent with previous studies using SD female rats that have shown that
oral gavage administration of ATZ at four daily doses of 50 mg/kg/day or higher can inhibit
the spontaneous proestrous LH surge (Foradori et al., 2009a), as well as the estrogeninduced and estrogen-plus-progesterone-induced LH surges (McMullin et al., 2004; Foradori
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et al., 2009a, 2014). In addition, recent work also indicated that there was no effect of ATZ
treatment in female SD rats exposed to ATZ for 14 days in adulthood, in female rats exposed
to ATZ prenatally through adulthood (postnatal day 133), or in females exposed from
weaning through adulthood (Breckenridge et al., 2015). The results from Breckenridge et al.
are consistent with the observations in the current study, where the 50 mg/kg/day dose,
although effective in attenuating the LH surge following four daily doses, was ineffective
following 8 or 14 days of treatment (with respect to peak LH and AUC).
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The timing of the appearance and disappearance of the effect of ATZ on the LH surge are
consistent with the observation that the LH surge returns to normal within 4 days of
terminating ATZ dosing (Foradori et al., 2009a). This is consistent with the rapid
pharmacokinetic clearance of ATZ and its chlorometabolites from plasma (Campbell et al.,
2016). However, in the present studies, the effect of ATZ on LH was reduced on day 8, 4
days after reaching its apparent maximum. The mechanism underlying the development and
attenuation of ATZ’s ability to inhibit the LH surge is unknown.
It is possible that an interaction between the acute effect of ATZ on the hypothalamicpituitary-adrenal (HPA) axis and the effect of ATZ on the HPA axis after short-duration,
high-dose exposure underlies the LH surge-inhibiting effect of ATZ (Cooper et al., 2000;
Foradori et al., 2009a, 2014). It is known that single high doses of ATZ or its monodealkylated chlorometabolites, DIA and DEA, result in increased plasma progesterone and
corticosterone levels within 15–30 min of dosing in female (Fraites et al., 2009) and/or male
(Laws et al., 2009) rats. Foradori et al. (2011) confirmed these findings for ATZ, and showed
that increased plasma corticosterone levels persisted for 12 hr following a single ATZ dose
of 200 mg/kg.
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However, HPA activation did not persist in female rats administered ATZ at a dose of 50
mg/kg/day for 7, 14, or 28 days (Foradori et al., 2017). In contrast, DACT, the final common
chlorometabolite of DEA and DIA (Campbell et al., 2016), did not activate the HPA axis
(Fraites et al., 2009; Laws et al., 2009). Despite the failure of DACT to activate the HPA
axis, in other experiments, DACT suppressed the LH surge in rats after 4 (Foradori et al.,
2011; Goldman et al., 2013), 30 (Minnema, 2001), or 180 days (Minnema, 2002) of
treatment.
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Furthermore, Foradori et al. (2011) showed that adrenalectomy abolished the effect of ATZ
on pulsatile LH (Foradori et al., 2009b), but did not alter its effects on the LH surge,
suggesting that adrenal corticosterone or progesterone may not be the sole mediators of the
inhibitory effect of ATZ on the LH surge. It is well known that progesterone, when delivered
at the appropriate time of day, can augment (Kamel and Kubajak, 1987; Gore et al., 2006) or
inhibit (Freeman et al., 1976; Kempers and Ryan, 1977; Attardi, 1984) the estrogen-induced
LH surge. Depending on the timing and magnitude of ATZ-induced progesterone release
from the adrenal gland, ATZ’s inhibition of the LH surge may be modulated by the shortlived spike of plasma progesterone following repeated administration of high doses of ATZ.
To determine what other factors might contribute to the dose- and time-dependent changes in
sensitivity of the LH surge to ATZ, we conducted multivariate regression analyses, where the
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magnitude of the variability in LH AUC accounted for by time- and dose-dependent
response parameters (BW loss, phase I, and phase II liver enzyme expression) was assessed.
These analyses indicate that dose level and the number of dose days had the largest effects
on the R2, followed by a modest contribution of BW loss. However, animals that received an
ATZ dose of 50 mg/kg/day sustained a BW gain reduction that was approximately the same
as the group of animals that received 100 mg/kg/day ATZ (Fig. 1), yet LH AUC was not
significantly different from control animals on day 8 or 14 (Fig. 3). In the 6.5 mg/kg/day
ATZ dose group, initial BW gain reductions recovered by days 2 through 4, and LH levels
were indistinguishable from controls by day 8. Furthermore, the analysis of the relationship
between the LH AUC and changes in BW gain during the dosing interval indicated that
these parameters were not correlated, irrespective of dose group.
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Cooper et al. (2000) reported that the LH surge of Long-Evans (LE), but not SD rats, was
significantly reduced after ATZ daily doses of 50, 100, 200, or 300 mg/ kg/day were
administered for 1 or 3 days. BW was unaffected by treatment in either SD or LE rats after
one or three doses, although after 21 days, high-dose LE rats displayed significantly reduced
BW. Goldman et al. (2013) reported that two doses of ATZ (100 mg/kg/day) had no effect on
BW, but a non-statistically significant reduction in LH AUC was observed. After four doses,
there was no effect on BW, but LH AUC was now significantly reduced in the ATZ group,
when compared to the controls. The authors attributed the non-significant effect of ATZ on
LH AUC after 2 days of treatment to individual animal variability in the LH AUC response,
with some animals responding with a robust reduction in LH AUC, while other animals were
more like controls. The data from Cooper et al. (2000) and Goldman et al. (2013) support
the conclusion from our study that the effect of ATZ on the LH surge is not linked to its
effect on BW.
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Among the CYP450 enzymes evaluated by Zimmerman et al. (2017), mRNA expression of a
number of CYP enzymes (CYP1A2, CYP3A18, CYP2E1 CYP2B2, CYP3A23/31,
CYP4A3, CYP3A9, and CYP2D4; Supplementary Figs. S1 and S2) displayed large, ATZdose-related, increased levels relative to controls. Average CYP2B expression, which
displayed the largest increase among all CYP enzymes evaluated (Supplementary Fig. S2),
was inversely proportional to LH AUC (see Fig. 7b). However, linear regression analysis
conducted using individual animal data indicated that CYP2B2 did not contribute much to
the R2 for LH AUC (Fig. 8).
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A similar analysis of GSH and GST indicated that both were dose-dependently induced
above baseline levels by repeated ATZ administration (Supplementary Figs. S3, S4, and S5).
Linear regression analysis indicated that GST enzymes contributed more in predicting the
effect of ATZ on LH AUC than did the CYP enzymes (Fig. 8). It is plausible that the ATZinduced increased synthesis of GSH and expression of GST enzymes contributed to the day
8 decrease in LH AUC in ATZ-treated animals. It is expected that increased levels of GSH
and GST in the liver would facilitate the conjugation and elimination of ATZ, DEA, and
DACT (Campbell et al., 2016), thereby attenuating the effect of ATZ on the LH surge. This
hypothesis is consistent with the results of a sensitivity analysis indicating that of the 84
parameters used in an ATZ-specific PBPK model, the rate of urinary clearance of DACT had
up to a 4.5-fold effect on the model-estimated internal dose of DACT (Breckenridge et al.,
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2016). It is also consistent with the observation that the tolerance of maize to chlorotriazines
is linked to higher levels of expression and activity of GST (Timmerman, 1989), and that
when weeds develop resistance to ATZ, it has been attributed to increased expression/
activity of GST (Anderson and Gronwald, 1991; Evans et al., 2017).
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In summary, the results of the current study demonstrate that ATZ, when administered orally
by gavage at a dose of 50 or 100 mg/kg/day for 4 consecutive days, is sufficient to impair the
estrogen-induced LH surge in ovariectomized female SD rats. The magnitude of this effect
appears to develop over the course of several days, since there was no significant effect on
LH peak amplitude or LH AUC after 1 to 3 days of treatment. Moreover, the ability of the
50-mg/kg/day dose to reduce the LH surge at 4 days was not completely sustained after 8 or
14 days of treatment, whereas a higher dose of 100 mg/kg/day still retained its ability to
suppress the LH surge through 14 days of exposure. Together, these data underscore the
importance of using the appropriate time period for testing rodent LH response dynamics to
endocrine-active chemicals. It also indicates that shifts in sensitivity to ATZ occur over
relatively short periods of time. The mechanism by which this change in sensitivity occurs
remains unresolved, although it is plausible that increased expression of phase I, or more
likely, phase II enzymes could underlie the observed changes.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1.
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Effect of atrazine (0, 6.5, 50, or 100 mg/kg/day) on mean (±SEM) BW (g) after 4, 8, or 14
days of treatment. If the SEM bars are not shown, they are smaller than the symbol used to
depict the mean. * p < 0.05 versus the control group on the same day.
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FIGURE 2.
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Effect of atrazine (100 mg/kg BW) on the LH surge. Graphs represent LH values across the
afternoon and evening following 1 (A), 2 (B), 3 (C), or 4 (D) daily doses of 100 mg/kg/day
atrazine, or 4 (D), 8 (E), or 14 (F) daily doses of 0, 6.5, 50, or 100 mg/kg atrazine. Atrazine
was administered by gavage at the time of lights on. Blood samples were taken at 6, 9, 11,
13, 15, and 18 hrs. after lights on. Dark bars on abscissa represent time of lights off. Each
point represents the mean +/− SEM of 9–15 individuals. If SEM bars are not shown, they are
smaller than the symbol used to depict the mean. * p < 0.05 versus controls; ** p < 0.01
versus controls.
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FIGURE 3.

Author Manuscript

Effect of atrazine on the peak LH surge amplitude (A, B, and C) or LH AUC (D, E, F) after
4, 8, or 14 days of atrazine administration by gavage at doses of 0, 6.5, 50, or 100 mg/kg/
day. LH peak was calculated as the highest value attained by each individual animal on one
of the six sampling occasions. Each bar represents the mean +/− SEM of 10–15 individuals.
* p < 0.05 versus controls; ** p < 0.01 versus controls.
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FIGURE 4.

Adaptation of the effect of atrazine on the LH AUC after 4, 8, or 14 doses.
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FIGURE 5.

R2, which estimated the relative contribution of three covariates (day, dose level, and BW
loss during the dosing period), to account for variance in the measured LH AUC in
experiment 2.
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FIGURE 6.
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(A) Panel A: Atrazine dose (6.5, 50, or 100 mg/kg/day) and time dependent (day 4, 8, or 14)
expression of CYP2B2 mRNA expression (Mean ± SEM fold change relative to controls).
Panel B: Group mean plasma LH AUC and fold change in liver CYP2B2 mRNA enzyme
expression in female SD rats administered atrazine at dose of 6.5, 50, or 100 mg/kg/day for
4 days (experiment 2). The regression equations were calculated using individual animal
data. Control data were from animals sacrificed after 4, 8, or 14 days. Panel C: Group mean
plasma LH AUC and fold change in liver CYP2B2 mRNA enzyme expression in female SD
rats administered atrazine at dose of 6.5, 50, or 100 mg/kg/day for 8 or 14 days (experiment
2). The regression equations were calculated using individual animal data. (B) Relationships
between mean plasma LH AUC and liver CYP2B2 mRNA enzyme expression after 4, 8, or
14 days of atrazine dosing.
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FIGURE 7.
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(A) Mean (±SEM) GST mRNA expression in the control and 100 mg/kg/day ATZ group
after 1, 2, 3, 4, 8, or 14 days. * p < 0.05 versus controls. (B) Mean (±SEM) GST liver
enzyme induction compared to LH AUC after 4, 8, or 14 daily atrazine doses.
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FIGURE 8.

R2, which estimated the ability of the number of dose days, daily dose level, and a third
covariate (BW loss, CYP enzyme expression, or GST enzyme expression) to account for
variance in the measured LH AUC in experiment 2; * indicates that R2 was statistically
significant (p < 0.05).
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Treatment × time

Dose
(mg/kg/day)

Sample
time (hr)

22.1 (< 0.01)
24.3 (< 0.01)
14.6 (< 0.01)

4.2 (0.04)a
6.7 (0.01)a
11.0 (p < 0.01)a

2 × (0, 100)

3 × (0, 100)

4 × (0, 100)

2.2 (0.06)

0.5 (0.76)

0.7 (0.60)

0.3 (0.93)

100

100

100

100

1300

All time points

All time points

All time points

83.5 (< 0.01)

137 (< 0.01)

73.2 (< 0.01)

16.8 (p < 0.01)a

13.4 (p < 0.01)

12.6 (p < 0.01)

4 × (0, 6.5, 50, 100)

8 × (0, 6.5, 50, 100)

14 × (0, 6.5, 50, 100)

3.1 (< 0.01)

1.7 (0.04)

3.1 (< 0.01)

1400, 1600
1400, 1600

50
100

0900, 1100, 1300

100

All time points

All time points

50

6.5

All time points

1100, 1300

6.5

< 0.01

1100, 1300

50
100

< 0.01

< 0.01

NS

< 0.05

NS

NS

< 0.01

< 0.05

< 0.01

NS

NS

NS

1300

6.5

Experiment 2: Effects of 4, 8, or 14 days of atrazine treatment on the LH surge

20.3 (< 0.01)

1 × (0, 100)

p -Value
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Bolded p -values indicate statistically significant differences (p < 0.05 or 0.01) between the designated treated and control groups.

Pairwise statistical comparison was performed using the Student’s t-test in experiment 1 and the Dunnett’s t-test in experiment 2.

a

Time

LH surge: Bonferroni t-test
Control × dose group

Experiment 1: Effects of 1, 2, 3, or 4 days of atrazine treatment on the LH surge

Treatment

0.2 (0.65)

Number of ATZ
doses (mg/kg/day)

LH surge: Two-way ANOVA
F statistic, (p -value)

< 0.01

NS

NS

< 0.05

NS

NS

< 0.01

< 0.05

NS

0.02

0.17

0.08

0.48

LH peak
amplitude

< 0.01

NS

NS

< 0.05

NS

NS

< 0.01

< 0.01

NS

0.02

0.08

0.22

0.37

LH
AUC

t-Test (p -value)1
Treatment group vs.
control group

Statistically significant effects of repeated daily doses of atrazine on the LH surge in experiments 1 and 2
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